AstraZeneca sells ex-US rights for Entocort to Tillotts

9 July 2015
mergers-acquisitions-big

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has entered into an agreement with Switzerland-based Tillotts Pharma, part of the Japanese Zeria Group (TYO: 4559), for the divestment of global rights, outside the USA, to Entocort (budesonide), a gastroenterology drug for patients with mild to moderate Crohn’s disease and ulcerative colitis.

Entocort is currently available in over 40 countries, with total product sales of $53 million outside the US in 2014. A regulatory submission for Entocort in Japan is anticipated in the coming months. In the USA, Teva Pharmaceutical Industries (NYSE: TEVA) markets a generic version of budesonide.

AstraZeneca to receive $215 million on completion of transaction

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical